Table 1 Results from Phase II study in cutaneous metastatic melanoma [14, 15]
Phase II Melanoma (NCT 00086866) | recMAGE-A3 + AS02B | recMAGE-A3 + AS15 | |
|---|---|---|---|
Primary endpoint | Clinical objective responses | - 1 PR (5-months) 5 SD (> 16 weeks) | 3 CR (11, 32+, 23+ months) 1 PR (7-months) 5 SD (> 16 weeks) |
Secondary endpoints | Safety | Well tolerated | Well tolerated |
|  | Overall survival | 19.9 month (95% CI: 15.4°; 25.6) | 31.1 months (95% CI: 20.0°; NR) |
| Â | Cellular immune response | Induced in 21% of patients | Induced in 76% of patients |